WO2011043538A3 - 실내 공기유래 세포밖 소포체를 포함하는 조성물 및 이의 용도 - Google Patents

실내 공기유래 세포밖 소포체를 포함하는 조성물 및 이의 용도 Download PDF

Info

Publication number
WO2011043538A3
WO2011043538A3 PCT/KR2010/005125 KR2010005125W WO2011043538A3 WO 2011043538 A3 WO2011043538 A3 WO 2011043538A3 KR 2010005125 W KR2010005125 W KR 2010005125W WO 2011043538 A3 WO2011043538 A3 WO 2011043538A3
Authority
WO
WIPO (PCT)
Prior art keywords
membrane vesicles
indoor air
extracellular membrane
respiratory diseases
present
Prior art date
Application number
PCT/KR2010/005125
Other languages
English (en)
French (fr)
Other versions
WO2011043538A2 (ko
Inventor
김윤근
고용송
김유선
최은정
홍성욱
이은영
홍복실
최준표
지영구
Original Assignee
주식회사이언메딕스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사이언메딕스 filed Critical 주식회사이언메딕스
Priority to CN201080045503.0A priority Critical patent/CN102573904B/zh
Priority to JP2012533068A priority patent/JP5860402B2/ja
Priority to EP10822183.9A priority patent/EP2486940B1/en
Priority to US13/499,653 priority patent/US8691522B2/en
Publication of WO2011043538A2 publication Critical patent/WO2011043538A2/ko
Publication of WO2011043538A3 publication Critical patent/WO2011043538A3/ko

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD

Abstract

본 발명은 실내 공기유래 세포밖 소포체를 포함하는 조성물 등에 관한 것이다. 또한 본 발명은 상기 세포밖 소포체를 이용하여 염증성 호흡기질환 및 폐암 등을 진단, 예방, 및/또는 치료하는 방법을 제공한다. 구체적으로, 본 발명은 실내 공기에 존재하는 세포밖 소포체를 동물에게 투여하여 호흡기질환 동물 모델을 제조하고, 상기 동물 모델을 이용하여 호흡기질환에 대한 예방 또는 치료 후보 약물의 검색 및/또는 발굴을 가능하게 하며, 호흡기질환에 대한 예방 및/또는 치료용 백신, 호흡기질환의 원인물질을 진단하는 방법, 호흡기질환의 발생 및 악화를 예방하기 위한 목적으로 실내 공기 중의 세포밖 소포체의 활성을 억제 또는 상기 세포밖 소포체를 제거하는 방법 등을 제공한다.
PCT/KR2010/005125 2009-10-08 2010-08-05 실내 공기유래 세포밖 소포체를 포함하는 조성물 및 이의 용도 WO2011043538A2 (ko)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN201080045503.0A CN102573904B (zh) 2009-10-08 2010-08-05 含有源于室内空气的细胞外小泡的组合物及其用途
JP2012533068A JP5860402B2 (ja) 2009-10-08 2010-08-05 室内空気由来細胞外ベシクルを含む組成物及びその用途
EP10822183.9A EP2486940B1 (en) 2009-10-08 2010-08-05 Composition comprising extracellular membrane vesicles derived from indoor air, and use thereof
US13/499,653 US8691522B2 (en) 2009-10-08 2010-08-05 Composition comprising extracellular membrane vesicles derived from indoor air, and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2009-0095620 2009-10-08
KR20090095620 2009-10-08

Publications (2)

Publication Number Publication Date
WO2011043538A2 WO2011043538A2 (ko) 2011-04-14
WO2011043538A3 true WO2011043538A3 (ko) 2011-06-30

Family

ID=43857241

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/005125 WO2011043538A2 (ko) 2009-10-08 2010-08-05 실내 공기유래 세포밖 소포체를 포함하는 조성물 및 이의 용도

Country Status (6)

Country Link
US (1) US8691522B2 (ko)
EP (1) EP2486940B1 (ko)
JP (2) JP5860402B2 (ko)
KR (1) KR101488902B1 (ko)
CN (1) CN102573904B (ko)
WO (1) WO2011043538A2 (ko)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101798176B1 (ko) * 2014-12-16 2017-11-15 주식회사 엠디헬스케어 세균 유래의 나노소포체를 이용한 세균성 감염질환 원인균 동정방법
KR20160101521A (ko) * 2015-02-17 2016-08-25 이화여자대학교 산학협력단 세균 유래 세포밖 소포체를 이용한 호흡기 염증성 질환의 진단방법
KR102418785B1 (ko) * 2015-09-25 2022-07-08 (주)프로스테믹스 식물 착즙물 유래 세포 외 소포체를 포함하는 피부 개선 및 탈모 방지용 조성물
KR101858840B1 (ko) 2016-01-15 2018-05-16 단국대학교 천안캠퍼스 산학협력단 집먼지진드기 유래 알레르겐에 의한 과민반응 면역조절제
KR101911893B1 (ko) * 2017-01-11 2018-10-29 주식회사 엠디헬스케어 세균유래 세포밖 소포에 의한 기도 면역기능이상 조절제
WO2017122915A1 (ko) * 2016-01-15 2017-07-20 단국대학교 천안캠퍼스 산학협력단 집먼지진드기 유래 알레르겐에 의한 과민반응 면역조절제
WO2017123025A1 (ko) * 2016-01-15 2017-07-20 주식회사 엠디헬스케어 세균유래 세포밖 소포에 의한 기도 면역기능이상 조절제
KR101833504B1 (ko) * 2016-12-26 2018-03-05 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 폐암 진단방법
WO2019066121A1 (ko) * 2017-09-28 2019-04-04 ㈜프로스테믹스 식물 유래 세포 외 소포체를 포함하는 조성물
KR102194286B1 (ko) 2018-02-08 2020-12-22 주식회사 엠디헬스케어 락토코커스 속 세균 유래 나노소포 및 이의 용도
KR102118197B1 (ko) * 2018-02-28 2020-06-02 주식회사 엠디헬스케어 마이크로코커스 속 세균 유래 나노소포 및 이의 용도
WO2019168327A1 (ko) * 2018-02-28 2019-09-06 주식회사 엠디헬스케어 마이크로코커스 속 세균 유래 나노소포 및 이의 용도
WO2019168331A1 (ko) * 2018-02-28 2019-09-06 주식회사 엠디헬스케어 슈도모나스 속 세균 유래 나노소포 및 이의 용도
JP7186470B2 (ja) * 2018-12-10 2022-12-09 エムディー ヘルスケア インコーポレイテッド コリネバクテリウム属細菌由来のナノ小胞及びその用途
WO2021049798A1 (ko) * 2019-09-10 2021-03-18 주식회사 엠디헬스케어 미생물 유래 소포에 대한 항체 기반 폐질환 진단 방법
KR102273232B1 (ko) * 2020-05-08 2021-07-06 코스맥스 주식회사 마이크로코커스 리래 균주 및 그의 피부 상태 개선 용도
US20240058393A1 (en) * 2020-12-28 2024-02-22 Md Healthcare Inc. Composition comprising micrococcus luteus-derived extracellular vesicle for prevention or treatment of metabolic disease
WO2022145680A1 (ko) * 2020-12-28 2022-07-07 주식회사 엠디헬스케어 마이크로코커스 루테우스 유래 세포외 소포를 포함하는 호중구성 폐질환의 예방 또는 치료용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050013831A1 (en) * 2001-12-17 2005-01-20 Foster Keith Alan Outer membrane vesicles from gram negative bacteria and use as a vaccine
WO2005035733A2 (en) * 2003-10-09 2005-04-21 Health Protection Agency Modified whole cell, cell extract and omv-based vaccines

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0213622D0 (en) * 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
GB0424092D0 (en) * 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
AU2007207519B2 (en) * 2006-01-19 2010-05-20 Research Corporation Technologies, Inc. Viable non-toxic gram negative bacteria
TW200848429A (en) * 2007-04-23 2008-12-16 Wyeth Corp Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
CN101820907B (zh) 2007-08-15 2013-05-01 切尔卡西亚有限公司 针对过敏原去敏化的肽
WO2009033276A1 (en) * 2007-09-11 2009-03-19 UNIVERSITé LAVAL Malva mosaic virus and virus-like particles and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050013831A1 (en) * 2001-12-17 2005-01-20 Foster Keith Alan Outer membrane vesicles from gram negative bacteria and use as a vaccine
WO2005035733A2 (en) * 2003-10-09 2005-04-21 Health Protection Agency Modified whole cell, cell extract and omv-based vaccines

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
LEE, EUN YEONG ET AL.: "Proteomics in Enterotoxigenic Staphylococcus Aureus Membrane Vesicles (abstract publication)", KHUPO 9TH ANNUAL INTERNATIONAL PROTEOMICS CONFERENCE: PROTEOMICS: FROM DISCOVERY TO FUNCTIONS, vol. 9, 25 May 2009 (2009-05-25), pages 88, XP008153778 *
MURPHY, T. F. ET AL.: "Construction of a mutant and characterization of the role of the vaccine antigen P6 in outer membrane integrity of nontypeable Haemophilus influenzae.", INFECT. IMMUN., vol. 74, no. 9, September 2006 (2006-09-01), pages 5169 - 5176, XP002587884 *
NICOLA, A. M. ET AL.: "Lipophilic dye staining of Cryptococcus neoformans extracellular vesicles and capsule.", EUKARYOT. CELL., vol. 8, no. 9, 22 May 2009 (2009-05-22), pages 1373 - 1380, XP008153476 *
SETHI, S. ET AL.: "New strains of bacteria and exacerbations of chronic obstructive pulmonary disease.", N. ENGL. J. MED., vol. 347, no. 7, 15 August 2002 (2002-08-15), pages 465 - 471, XP008153479 *
SHOEMAKER, D. R. ET AL.: "Intranasal delivery of group B meningococcal native outer membrane vesicle vaccine induces local mucosal and serum bactericidal antibody responses in rabbits.", INFECT. IMMUN., vol. 73, no. 8, August 2005 (2005-08-01), pages 5031 - 5038, XP008153483 *

Also Published As

Publication number Publication date
US20120192295A1 (en) 2012-07-26
JP2013507354A (ja) 2013-03-04
KR20110038575A (ko) 2011-04-14
EP2486940A2 (en) 2012-08-15
US8691522B2 (en) 2014-04-08
KR101488902B1 (ko) 2015-02-03
JP5860402B2 (ja) 2016-02-16
CN102573904A (zh) 2012-07-11
CN102573904B (zh) 2016-02-10
EP2486940B1 (en) 2017-10-04
WO2011043538A2 (ko) 2011-04-14
JP2015091241A (ja) 2015-05-14
EP2486940A4 (en) 2013-08-21
JP6293649B2 (ja) 2018-03-14

Similar Documents

Publication Publication Date Title
WO2011043538A3 (ko) 실내 공기유래 세포밖 소포체를 포함하는 조성물 및 이의 용도
WO2011027971A3 (ko) 장내 공생 세균유래 세포밖 소포체, 및 이를 이용한 질병모델, 백신, 후보 약물 탐색 방법, 및 진단 방법
CR11472A (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
CL2007002099A1 (es) Compuestos derivados de 3h-espiro(1-benzofuran-2,4'-piperidina); proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento de enfermedades respiratorias, tales como epoc y asma.
WO2011027990A3 (ko) 그람 양성 세균유래 세포밖 소포체 및 이의 용도
IL229070B (en) Methods for identifying and diagnosing lung diseases using their classification systems and sets
WO2012110770A3 (en) Combination of glycopyrrolate and a beta2 -agonist
GB201205632D0 (en) Method and apparatus
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
AU2012205878A8 (en) miRNA for treating diseases and conditions associated with neo-angiogenesis
BR112012017107A2 (pt) sistemas para administrar um fluxo de gás de respiração a uma via aérea de um paciente, método de ventilar um paciente e sistema para ventilar um paciente
EP2491932A3 (en) Use of biomarkers for monitoring the course of treatment of a pulmonary disease upon treatment with treprostinil
WO2012158780A3 (en) Lung cancer signature
BR112012009214A2 (pt) compostos
WO2012149157A3 (en) Heterocyclic compounds for the inhibition of pask
CL2008003549A1 (es) Compuestos derivados de glucocorticoides; procedimientos de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de enfermedades a la piel como eczema, afecciones a la nariz, garganta y pulmones como rinitis o asma, enfermedades inflamatorias del intestino, oculares y autoinmunes.
CL2012001432A1 (es) Producto de combinacion farmacéutica que comprende bromuro de 4-[hidroxi-(difenil)-metil]-1-{2-[(fenil-metil)-oxi]-etil}-1-azonia-biciclo-[2.2.2]-octano y trifenil-acetato de 4-{(1r)-2-[(6-{2-[(2,6-dicloro-bencil)-oxi]-etoxi}-hexil)-amino]-1-hidroxi-etil}-2-(hidroxi-metil)-fenol; y su uso para tratar enfermedades respiratorias.
WO2008144720A3 (en) Inhibitors of igf-1r signaling for the treatment of respiratory disorders
BRPI0808333A2 (pt) extrato bacteriano para doenças respiratórias e processo para sua preparação
BR112013001753A2 (pt) método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada.
BR112013001297A2 (pt) composições farmacêuticas e respectivo uso e método de tratamento de doença ou condição respiratória
CL2007003754A1 (es) Compuestos derivados de aril(heteroaril)alquil-amina; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como bronquitis, enfisema pulmonar y epoc.
WO2007098106A3 (en) Respiratory tract delivery of interferon-tau
WO2014018668A3 (en) Aerosol pirfenidone and pyridone analog compounds
DE112010004298A5 (de) Vorrichtung zum absaugen des sputums bei tracheotomie-patienten sowie innenkanüle für eine trachealkanüle

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080045503.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10822183

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 13499653

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2012533068

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2010822183

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010822183

Country of ref document: EP